Published in FDA Law Weekly, August 12th, 2004
Net sales for the 2nd quarter were $144.0 million, compared to $152.0 million in the 2nd quarter of 2003. Net income for the 3 months ended June 30, 2004 was $31.5 million compared to $45.2 million in the comparable 2003 period. Adjusted net income for the 3 months ended June 30, 2004 was $37.8 million compared with $46.1 million in the same period in 2003.
Diluted earnings per share for the 3 months ended June 30, 2004 were $0.24 compared with $0.34 in 2003. Adjusted...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of FDA Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.